跳至主要内容
临床试验/NCT05233241
NCT05233241Unknown不适用

Identification of the Causative Drug in Drug-induced Acute Interstitial Nephritis

Assistance Publique - Hôpitaux de Paris2 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2022年7月最近更新:
适应症

试验速览

阶段
不适用
入组人数
44
试验地点
2
主要终点
Proportion of patients with at least one allergological test (in vitro or in vivo) positive for a suspected molecule

研究概览

简要总结

Drug-induced acute interstitial nephritis (DAIN) is a rare entity characterized by acute renal failure linked to inflammation of the renal parenchyma secondary to allergenic drug exposure. Treatment is based primarily on the precise identification of the causative drug and its final elimination. Currently, the identification of the causative drug is based on clinical presumption. There is no test to formally identify the causative drug. On the other hand, in-vitro allergological tests (lymphocyte transformation test in particular) have been developed in the course of immuno-allergic drug toxiderma linked to delayed type IV hypersensitivity to identify the causal drug. These tests have not been studied during DAIN, but their value in drug-induced eruption is indisputable. The objective of our study is to determine whether in vitro allergy tests can identify the causative drug during DAIN. If the in vitro tests fail, they will be supplemented by allergological skin tests.

详细描述

Acute interstitial nephritis (AIN) is a nosological entity characterized by the presence of an inflammatory infiltrate and edema in the renal interstitium responsible for acute renal failure. AIN represent 1-3% of all renal biopsies in some studies and up to 20% of diagnosis in acute renal failure. There are several etiologies of AIN: drug-induced (DAIN), immunological, infectious and idiopathic. In a North American single-center retrospective study of 133 patients with histologically proven AIN between 1993 and 2001, the most common cause was drug-induced (70%). The involved drugs were mainly antibiotics (49%), proton pump inhibitors (14%) and non-steroidal anti-inflammatory drugs (11%). More than 250 drugs can cause DAIN and it is established that any drug can be responsible for DAIN.

The clinical presentation of DAIN is aspecific and variable depending on the drug class involved. It usually occurs 7 to 10 days after the introduction of the causative drug, but this delay may be one day with some antibiotics or several months with non-steroidal anti-inflammatory drugs or proton pump inhibitors. The only consistent manifestation is acute or subacute renal failure, requiring extra-renal epuration in 40% of cases. Clinically, patients may be asymptomatic or present aspecific clinical manifestations such as arthralgias (45%), fever (36%), and skin rash (22%). Biological examinations systematically reveal elevated creatinine levels and, to varying degrees, eosinophilia (35%), microhematuria (67%), leukocyturia (82%) and non-nephrotic proteinuria (93%). The classic triad of fever, rash and eosinophilia is highly suggestive of DAIN and type IV hypersensitivity reaction but is present in only 10-15% of cases. The diagnosis of DAIN should therefore be systematically evoked in the presence of unexplained acute renal failure associated with recent drug exposure.

The pathophysiology of DAIN remains poorly understood. It would involve a drug hypersensitivity reaction. This pathophysiological hypothesis is based on several observations:

(1) DAIN is an idiosyncratic and non-dose-dependent pathology, (2) the presence of eosinophils in the inflammatory infiltrate is frequent (3) it may be accompanied by a systemic hypersensitivity reaction (skin rash, liver damage, eosinophilia), (4) there is usually a 7-10 day interval between the onset of drug exposure and the onset of acute renal failure. Delayed hypersensitivity (Gell and Combs type IV) in which T cells play a central role is the current hypothesis in the pathophysiology of DAIN. Moreover, the preponderance of T lymphocytes in the interstitial inflammatory infiltrate, the absence of immunoglobulin and complement deposits in direct immunofluorescence in the majority of cases also pleads in favour of a delayed hypersensitivity of type IV mediated by T lymphocytes.

The kidney is a target organ for delayed hypersensitivity for 2 main reasons. First, blood flow is high in the kidneys where potential antigens are filtered, secreted, metabolized and/or concentrated. On the other hand, the kidney plays a central role in the excretion of most drugs. These 2 mechanisms explain the particular susceptibility of the kidneys to delayed hypersensitivity due to the exposure of the renal parenchyma to numerous antigens from pharmacological agents and their metabolites.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18 years
  • Acute renal failure with an eGFR < 60 ml/min/1.73m2 by CKD-EPI managed in the participating centers in the study
  • Histologically proven DAIN by renal biopsy (anatomopathological reading in each center according to local habits): presence of an infiltration of inflammatory cells (lymphocytes, monocytes, plasmocytes, eosinophils) in the interstitium accompanied by a variable degree of interstitial edema and fibrosis
  • Successful diagnosis of DAIN with identification of one or more attributable drugs
  • Signed consent
  • Membership in a social security plan or entitled person

排除标准

  • Anatomic-clinical suspicion of AIN of infectious or autoimmune cause or associated with systemic diseases (Sjögren's syndrome, sarcoidosis, tubulointerstitial nephritis syndrome and uveitis, systemic lupus, IgG4-associated disease)
  • Kidney transplant patients
  • Current immunosuppressive treatment at the time of allergological testing (test results not interpretable)
  • Participation in other interventional research
  • Patient under state medical assistance
  • Patient deprived of liberty or under legal protection
  • Pregnancy

结局指标

主要结局

Proportion of patients with at least one allergological test (in vitro or in vivo) positive for a suspected molecule

时间窗: 6 months

In vitro tests are lymphocyte transformation test, ELISPOT-Interferon gamma, measurement of CD154 expression. In vivo (skin) tests are patch test, prick test, intradermal test

次要结局

  • Proportion of patients with at least one positive result in one of the three in vitro allergological tests(6 months)
  • Proportion of patients with positive results for each skin test in case of negative in vitro tests(6 months)
  • Proportion of patients with a positive result for one of the three skin tests in case of negative in vitro test(6 months)
  • Proportion of patients with positive results for each in vitro allergy test performed 3-18 months after an episode of histologically confirmed NIAM(6 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验